The NGS method was performed in 2 patients (Patients 1 and 6), the results of which showed a low frequency of ALK gene fusion, 0.42% and 15.15%, respectively (the tumor cells in these 2 cases accounted more than 90% of the total cells examined), and revealed a novel fusion variant E13:EXOC6B:A20 in Patient 1 which was confirmed by Sanger sequencing. The gene discussed is ALK; the disease is neoplasm.